8th EACTS Mechanical Circulatory Support Summit
- 7 – 9 Nov 2024
- Prague, Czech Republic
- In Person
Event Information
-
Date/Duration
7 – 9 November 2024
- Location
Prague, Czech Republic
See HERE for more information- Chairmen
I Netuka, Prague; G Färber, Homburg Saar; D Zimpfer, Vienna; J Gummert, Bad Oeynhausen; V Falk, Berlin; F Gustafsson, Copenhagen
- Summit Format
In-person meeting
Interactive lectures
Live-in-a-box cases
Keynote presentations- Summit Fee
Members: €610
Non-Members: €710
Residents: €390- Target Audience
Cardiologists, heart failure cardiologists, emergency and ICU specialists (ECLS), cardiac surgeons, perfusionists, heart failure nurses and VAD coordinators, medical industry (cardiac device including ECMO development and production). Pediatric cardiologists and congenital heart disease surgeons.
- Abstract Poster Submission
Abstract poster submissions are now closed.
Thank you for your submissions- 8th MCS Rising Stars Quiz
We are happy to announce that for the first time, delegates are invited to submit a team to participate in the MCS annual quiz.
Members of the team should be from the same country or the same institution and may have a maximum of 4 participants.
Spaces are limited, and we may not be able to accommodate all that apply, so please register your interest by emailing [email protected] and we will get back to you.- Accreditations
This course is Ethical MedTech compliant, full details can be found here.
The 8th EACTS Mechanical Circulatory Support Summit, Prague, Czech Republic 07/11/2024 – 09/11/2024, has been accredited
by the European Accreditation Council for Continuing Medical Education (EACCME®) with 17.0 European CME credits
(ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational
activity.EACTS Academy terms and conditions.
The 8th EACTS Mechanical Circulatory Support Summit will be an in-person meeting and run from 7-9 November 2024 in Prague, Czech Republic
Summit programme
08:00 Introduction
I Netuka, Prague; G. Färber, Homburg Saar; D Zimpfer, Vienna; J Gummert, Bad Oeynhausen; F Gustafsson, Copenhagen, E Potapov, BerlinWelcome address from the Czech Society of Cardiology and the Czech Cardiovascular Surgical Society
P Ostadal, Prague; J Vojacek, Hradec Kralove08:15 Session 1: Advanced HF: Gaps in therapy and communication Moderators: N Uriel, New York; J Gummert, Bad Oeynhausen; G. Färber, Homburg Saar; P Ostadal, Prague Residual risks beyond drugs and pacemakers in advanced HF – 30.000 feet perspective
U Jorde, New YorkTimely recognition and referral of advanced HF
M Kanwar, PittsburghWho needs more than interventional procedures and CIED in advanced HF – a continuum of care
A Fardman, Ramat GanGrowing acute and chronic heart failure networks of excellence – one approach fits all?
F Schönrath, BerlinHow should we communicate risks and benefits of LVAD therapy?
F Gustafsson, CopenhagenPanel discussion 10:00 Break 10:30 Session 2: Advancing outcomes with contemporary LVAD technology Moderators: S Rojas Hernandez, Bad Oeynhausen; Z Tucanova, Prague; G. Färber, Homburg Saar Optimizing patient and LVAD interaction – diagnostic sensors and therapeutic clips
N Uriel, New YorkAortic interventions in LVADs: at implant or later?
F Pagani, Ann ArborOutflow graft complications: prevention, early recognition and repair
M. Müller, BerlinSurgical management of driveline infection
J Mulzer, BerlinPanel discussion 12:00 Lunch 13:00 Session 3: The paradigm of myocardial recovery with MCS Moderators: J Riebandt, Vienna; J Vojacek, Hradec Kralove; J Stehlik, Salt Lake City; I Netuka, Prague Bridging to recovery in high-risk cardiac surgery – expanding the opportunity
E Potapov, BerlinProtected CABG – turning impossible to reality
A Abd El Al, BerlinImplications of partial recovery with LVADs – is there still a role for medical therapy?
F Gustafsson, CopenhagenWeaning-off from durable LVAD. Who, when? Lessons learned from VAD wean registry
J Stehlik, Salt Lake CityDeactivation of LVAD support for myocardial recovery – surgical perspectives
D Zimpfer, ViennaPanel discussion 14:30 Break 15:00 Session 4: Data and guidelines in MCS – forging new directions Moderators: F Pagani, Ann Arbor; J Mulzer, Berlin; A Fardman, Ramat Gan; D Zimpfer, Vienna Transatlantic guidelines in MCS: An Update
E Potapov, BerlinEUROMACS Registry: Pearls of wisdom
K Veen, RotterdamArtificial intelligence and durable MCS
M Kanwar, PittsburghPanel discussion 16:00 Session 5: Successful LVAD bridge to transplantation Moderators: R Venkateswaran, Manchester; R Tedford, Charleston; S Rojas Hernandez, Bad Oeynhausen; M Konarik, Prague LVADs and allosensitization – challenges, solutions and opportunities
J Stehlik, Salt Lake CityVasoplegia and PGD after HTx with MCS bridge
Y Barac, Tel AvivDebate: Optimal donor organ procurement strategies in LVAD patients – Normothermic oxygenated perfusion for LVAD transplants – only the best is good enough!
I Netuka, Prague– Hypothermic oxygenated and non-oxygenated procurement strategies – do not over do!
A Zuckermann, ViennaPanel discussion 17:30 Moderated poster session & welcome reception 19:00 Close 08:00 Session 6: Manage the patient, not the pump only! Moderators: M Müller , Berlin; P Ivak, Prague; F Kaufmann, Berlin; K Veen, Rotterdam Assessing QOL in LVAD recipients
F Calvo, MilanPatient education: before and after implant
C Francescon, MilanCaregiver burden and support
A Recio-Platero, ValladolidTelemedicine in ambulatory MCS population
F Kaufmann, BerlinPanel discussion 09:00 Featured lecture
Opening New Horizons in the End Stage HF – Robotic Future of Heart Transplant
F Khaliel, Riyadh09:15 Session 7: Have we advanced outcomes in Cardiogenic Shock? Moderators: J Belohlavek, Prague; P Lanmüller, Berlin; M Özbaran, Izmir; S Patel, New York Phenotyping to a therapeutic success in Cardiogenic Shock
M Kanwar, PittsburghDebate: – PRO: Danger ahead! All patients with MI-CS should be supported with a mAFP
E Potapov, Berlin– CON: Danger ahead! All patients with MI-CS should be supported with a mAFP
M Mehra, BostonECLS in CS – quo vadis?
R Lorusso, MaastrichtCombination is a right solution – shaken, not stirred…!
G Nersesian, BerlinPanel discussion 10:35 Break 11:05 Session 8: Novel concepts in Durable LVADs Moderators: J Gummert, Bad Oeynhausen; A Loforte, Turin; M Kanwar, Pittsburgh; I Netuka, Prague Preconditioning for better outcomes with durable LVAD: a key to success!
P Lanmüller, BerlinAnticoagulation strategies in continuous flow LVADs – VKA or DOAC?
Z Tucanova, PragueThe Paradox of non-surgical bleeding in durable VADs
M Mehra, BostonGetting closer to smart pumping with LVADs – the future is now?
N Uriel, New YorkAn ideal LVAD driveline – Born in New England
M Mehra, BostonA new driveline system for LVADs – Born in Europe
A Kourouklis, ZurichPanel discussion 12:30 8th MCS Rising Stars Quiz Moderators: E Potapov, Berlin; J Riebandt, Vienna; N Uriel, New York; I Netuka, Prague 13:00 Lunch 14:00 Session 9: Ongoing pivotal trials and designs in MCS Moderators: R Lorusso, Maastricht; N Uriel, New York; F Gustafsson, Copenhagen; P Ivak, Prague Learning from the ARIES pivotal trial: Novel insights
U Jorde, New YorkTEC – LVAD Trial
M Mehra, BostonRapid fire updates on ongoing trials: Fully magnetically levitated LVAD I
F Pagani, Ann ArborRapid fire updates on ongoing trials: Fully magnetically levitated LVAD II
J Riebandt, ViennaRapid fire updates on ongoing trials: Fully implantable intraventricular LVAD
I Netuka, PraguePanel discussion 15:20 Session 10: What’s new in the pipeline Moderators: M Morshuis, Bad Oeynhausen; E Potapov, Berlin; M Hulman, Bratislava; T Yagdi, Izmir Industry updates Panel discussion 16:15 Break 16:45 Session 11: When supporting one ventricle is not enough Moderators: U Jorde, New York; D Zimpfer, Vienna; Y Barac, Tel Aviv; F Pagani, Ann Arbor Deeper understanding of RHF in MCS
R Tedford, CharlestonAre we any closer in risk stratification with LVADs?
U Jorde, New YorkSurgical options for durable biventricular support
S Rojas Hernandez, Bad OeynhausenXenotransplantation and biomechanical heart: The future of a BioBIVAD?
M Mehra, BostonPanel discussion 18:00 Close 08:00 Session 12:Complex cases and creative solutions Moderators: M Özbaran, Izmir; A Fardman, Ramat Gan; H Gasparovic, Zagreb; J Mulzer, Berlin Vienna
D Zimpfer, ViennaIzmir
T Yagdi, IsmirTurin
A Loforte, TurinBad Oyenhausen
M Morshuis, Bad OyenhausenPrague
P Ivak, PragueManchester
R Venkateswaran, Manchester09:15 Session 13: Paediatric MCS Moderators: U Kervan, Ankara; D Zimpfer, Vienna; M Schweiger, Zurich MCS in the neonate – best solutions and outcomes
D Zimpfer, ViennaHow small is small for durable LVAD bridging in peds? Clear cut-off or fluid target?
U Kervan, AnkaraPeds and MCS: Stunned field or innovative arena?
M Schweiger, ZurichExperience with implantable LVAD in children in China
M Sun, HangzhouPanel discussion 10:30 Break 11:00 Session 14: Video sessions: How I do it… Moderators: Z Tučanová, Prague; G Nersesian, Berlin; M Konarik, Prague; S Rojas Hernandez, Bad Oeynhausen Tel Aviv
Y Barac, Tel AvivZagreb
H Gasparovic, ZagrebBeijing
X Zhou, BeijingBerlin
N Cholevas, Berlin11:40 Closing Remarks
M Mehra, Boston; F Gustafsson, Copenhagen; J Gummert, Bad Oeynhausen; E Potapov, Berlin; D Zimpfer, Vienna; I Netuka, Prague12:00 Close Programme and faculty subject to change.
Chairmen
Faculty
- Location